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The fragment-centric design promises a means to develop complex xenobiotic protein surface mimetics,
but it is challenging to find locally biomimetic structures. To address this issue, foldameric local surface
mimetic (LSM) libraries were constructed. Protein affinity patterns, ligand promiscuity and protein
druggability were evaluated using pull-down data for targets with various interaction tendencies and
levels of homology. LSM probes based on H14 helices exhibited sufficient binding affinities for the
detection of both orthosteric and non-orthosteric spots, and overall binding tendencies correlated with
the magnitude of the target interactome. Binding was driven by two proteinogenic side chains and LSM
probes could distinguish structurally similar proteins with different functions, indicating limited
promiscuity. Binding patterns displayed similar side chain enrichment values to those for native protein–
protein interfaces implying locally biomimetic behavior. These analyses suggest that in a fragment-
centric approach foldameric LSMs can serve as useful probes and building blocks for undruggable
protein interfaces.Introduction
Protein surface mimetics are chemical tools that target protein–
protein interactions (PPIs) that are undruggable with small
molecules.1–3 Although pioneering studies demonstrated the
possibility of ribosome-assisted coupling of amino acids with
non-natural backbones,4–7 in vitro directed evolutionary
approaches8 are not routinely available for searching and opti-
mization of fundamentally xenobiotic surface mimetic struc-
tures.9–11 Four major experimental chemical approaches and
their combinations have been applied to address this problem:
(i) screening of large surface mimetic libraries,10,12,13 (ii) top-
down mutational design based on known ligands,14–21 (iii)
bottom-up design and assembly starting from structural
hypotheses,3,22–31 and (iv) the fragment-centric system chemistry
approach leading to self-assembling ligands.32 Recentity of Szeged, Dóm tér 8, H6720, Szeged,
zeged.hu
roup, University of Szeged, Dóm tér 8,
ersity of Szeged, Somogyi u. 4., H6720,
d University, Pázmány Péter sétány 1/C,
elte.hu
tory, Institute of Genetics, Biological
Szeged, Hungary
SI) available: Experimental procedures,
ns, and peptide characterisation data.
10398theoretical and experimental results strongly support that
fragment-centric design built on recognition elements of
reduced structural complexity is highly promising for the
construction of surface mimetic ligands.33–35 It is also in accord
with the fragment-centric approach that protein interfaces are
highly degenerate and strongly interconnected, and interface
geometries are not dominated locally by specic secondary
structure types.36,37 To develop the fragment-centric concept
further, the present study aimed to nd minimal motifs that
can serve as local surface mimetics (LSM) with sufficient affinity
to probe otherwise undruggable protein surfaces. Dissociation
constants below 100 mM, the fragment-based drug design
limit,38 would facilitate observation of protein-specic binding
patterns and their potential application as surface mimetic
building blocks.
Our hypothesis was that the shortest foldamer sequences
with folding tendency in water can be used as LSM probes
(Fig. 1). The shortest water-stable foldameric structures are b-
peptidic hexamer helices stabilized by a number of cyclic side
chains.39–41 These sequences display only two proteinogenic side
chains on the same side that can be strongly shielded from the
solvent by the bulky scaffold and the cyclic side chains. While
longer foldameric sequences have been experimentally shown
to recognize protein surfaces and inhibit protein–protein
interactions (PPIs) for targets such as hDM2,42,43 the Bcl-xL
family,44 gp-41,45,46 the VEGF-receptor,47 and b-amyloid oligo-
mers,22 the general druggability of protein interfaces with fol-
dameric secondary structures has not been established. ThisThis journal is © The Royal Society of Chemistry 2020
Fig. 1 Design of local surface mimetic probe libraries using short
foldamers. H14 scaffold (a), H12 scaffold (b), library composition
showing sublibrary grouping (c), and structures of H14 and H12 helices
(d).
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View Article Onlinemight cast doubt on the general compatibility with protein
surfaces that unnatural backbone segments are oen not
tolerated at protein–foldamer interfaces for ligands derived
from natural templates in a top-down design scenario.48,49 In
contrast, compatibility was displayed toward some bottom-up
designed foldameric sequences,50 which led to high-affinity
ligands.
Besides sufficient affinity (druggability), ligand promiscuity is
an equally important problem for the design of specic surface
mimetic ligands.51 It is especially challenging to handle protein
interface similarity and ligand promiscuity when exposed protein
surfaces are targeted. The relevance of this point for foldamers is
indicated by the fact that the chemical space of non-natural resi-
dues in bioactive sequences is focused on aliphatic and aromatic
hydrophobic side chains that are primarily responsible for ligand
promiscuity and non-specic binding.52,53 Literature examples
exemplify the existence of this phenomenon for peptidic54 and
aromatic oligoamide foldamers.25,55 For acceptable LSM probes,
druggability and promiscuity properties should be in balance,
mimicking the behaviour of natural proteins. The number of
known interactions, and therefore, current knowledge, is limited
for druggability–promiscuity properties of foldamers. This situa-
tion calls for a systematic approach that generates data on
protein–foldamer interactions and facilitates an understanding of
molecular recognition patterns depending on the side chain
composition, secondary structures of foldamer segments, and
target protein surfaces.This journal is © The Royal Society of Chemistry 2020In this work, the druggability–promiscuity problem for folda-
meric LSMs is addressed with a bottom-up fragment-centric pull-
down methodology. To test these parameters, target proteins that
display different levels of interface similarity and promiscuity in
their own PPI network were selected. Aer mapping LSM binding
ngerprints, we found that proposed probes displayed biomi-
metic features on the protein test set, suggesting the suitability of
short foldameric sequences to probe protein surfaces and serve as
surface mimetic building blocks.Results
Foldameric LSM probe libraries
Peptide sequences constructed from b-amino acid residues exhibit
a strong tendency to fold into secondary structures at short chain
lengths, and the specic geometry is controlled by the backbone
stereochemistry pattern and topology of structure-inducing side
chains.41,56 Here, helices H14 and H12 were utilized. The closely
packed side chain distances in a-helices (Cai –C
a
i+3 z 5 Å and C
a
i –
Cai+4 z 6 Å) and in b-sheets (C
a
i –C
a
i+2 z 6 Å and “sideways” C
a
i –
Cai+nz 5 Å) are comparable with the closest side chain distances in
foldameric helices H14 (Cbi –C
b
i+3 z 5 Å) and H12 (C
b
i –C
b
i+2 z 6 Å).
Helix H14 exhibits a strong tendency to fold and its side chains are
oriented in parallel. Helix H12 is conformationally less stable in
aqueousmedium, demonstrating an elongated geometry, and side
chains are juxtaposed with a small tilt angle.41
These secondary structures can be stabilized by cyclic side
chain residues so that they display folding at lengths of hexamers
and octamers for H14 ((1S,2S)-2-aminocyclohexanecarboxylic acid,
ACHC) and H12 ((1S,2S)-2-aminocyclopentanecarboxylic acid,
ACPC), respectively. Such oligomers allow two proteinogenic side
chains that point to the identical face of the helix to be incorpo-
rated into the sequence (Fig. 1). Sixteen different b3-amino acids
were substituted at positions R1 and R2 generating altogether 512
local surface mimetics. LSM probes were synthesized and
screened as sublibraries (L1–L4) (Fig. 1c).
This library includes a considerable fraction of peptide fol-
damers that fold at such a short chain length. These peptides
can be considered as minimally folded building blocks in the
peptide foldamer space.32 These structural units can display
a surface area of ca. 500 Å2 toward a protein surface, which can
provide the binding free energy for affinities in the range of 1–
500 mM. Such affinity is sufficient for probing the surface and is
useful for subsequent fragment-based design.Test protein set
Five proteins (Table 1) were selected based on numbers of their
interacting protein partners (Fig. 2), levels of interprotein
structural homology, and types of interactions (protein–protein,
protein–carbohydrate). The reference protein in this set was
CaM,57 a highly pleiotropic molecule that plays a vital role in
every eukaryotic cell. It displays EF-hand motifs and mediates
an extremely large number of signal pathways via control of
enzyme and ion channel activities in a Ca2+-dependent manner.
Two additional EF-hand proteins with high structural homology
were selected from the S100 family: S100A4 and S100B,58 bothChem. Sci., 2020, 11, 10390–10398 | 10391
Table 1 Characteristics of applied protein probes
CaM S100A4 S100B Gal-1 RecQ-WH
Helix content (%) 62 55 58 0 50
b-sheet content (%) 4 3 2 54 13
Number of PPIsa 645 67 41 5 1
Molecular weight (kDa) 16.8 11.7  2b 10.7  2b 14.6  2b 12.9
Isoelectric pointc 4.09 5.85 4.52 5.30 10.18
a Average values from databases, BioGRID, Wiki-Pi, GPS-Prot, IntAct, and APID. For Gal-1, NPPI is given based on the review of Camby et al.66
b Homodimers. c Calculated values based on amino acid composition.
Fig. 2 Surface representation and PPI network of selected proteins. PPI data were obtained from BioGRID,61 Wiki-Pi,62 GPS-Prot,63 IntAct64 and
APID.65 For the lectin Gal-1, NPPI is based on ref. 66.
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View Article Onlineimportant pharmacological targets for cancer treatment.59
S100A4 is involved in tumour progression and metastasis and
has many interacting partners. S100B is expressed in
melanocyte-derived tumours and mature astrocytes,60 where it
plays an important role in neurite extension. Numbers of its
known protein partners are signicantly less than that for
S100A4. Galectin-1 (Gal-1) and the winged helix domain of RecQ
helicase (RecQ-WH) were used as target models with low
tendency to form PPIs. Gal-1 has an immunosuppressive effect,
promoting cancer progression and metastasis through recog-
nition of b-galactoside motifs on cell surface glycoproteins.66
Gal-1 has a b-sandwich structure with a jelly roll topology,67–69
that may interact with proteins in a carbohydrate independent
manner.66,70–72 RecQ is a prokaryotic intracellular ATP-
dependent DNA helicase, which plays important roles in DNA
damage response, DNA recombination, replication, and
repair.73,74 RecQ interacts with the disordered C-terminal of the
single-stranded DNA-binding protein (SSB) through its WH
domain, which is the single PPI reported for RecQ-WH.75 All
selected targets exhibit solvent exposed shallow binding sites;
however, CaM is able to wrap around a-helices with special side
chain motifs, thereby forming a hydrophobic pocket.76,77 For
competitive binding studies, peptide motifs of PPI partners
were selected from the following proteins: transient receptor
potential cation channel subfamily V member 1 (TRPV1), non-
muscle myosin IIA (NMIIA), ribosomal S6 kinase 1 (RSK1),
and SSB, for CaM, S100A4, S100B, and RecQ-WH, respectively.10392 | Chem. Sci., 2020, 11, 10390–10398LSM affinity patterns indicate secondary structure dependent
structural compatibility
Pull-down assays with immobilized test proteins and folda-
meric LSM libraries were carried out. Proteins were equilibrated
with LSM probes, and equilibrium bound fractions (FB) were
determined from the unbound fractions measured by HPLC-MS
methods. Hits were corrected with background binding of the
resin. The protocol allowed all binding events to equilibrate
irrespective of affinity, specicity, and binding kinetics. This
was essential to judge overall druggability and promiscuity.
Importantly, the concentration of protein and the total
concentration of foldameric LSMs were equimolar, which
minimized competition between the probes. This experimental
setup approximated independent binding of individual library
members. Results were visualized as heat maps of dissociation
constants (Fig. 3). Considering the experimental error of FB (see
ESI, Fig. S1†), the affinity limit was set at 150 mM to lter
successful hits (Fig. 3, indicated in red), which is 50 mM above
the 100 mM guideline normally applied in fragment-based drug
design.38
A number of hits were obtained for all proteins studied,
which supports the hypothesis that foldameric LSMs can
display sufficient contact area toward target proteins (Fig. 4).
Helical geometry had profound effects on binding tendency.
Helix H12 yielded fewer hits in general than did H14. Moreover,
binders having the H12 skeleton in the affinity range 1–10 mMThis journal is © The Royal Society of Chemistry 2020
Fig. 3 Binding patterns of foldameric LSM probes represented as heat
maps in the KD dimension (in mM). Apparent dissociation constants are
given for H14- and H12-helical LSM libraries. One letter codes dis-
played at the headings of the rows and columns correspond to the
proteinogenic side chains of the b3-homo-amino acids used in the R1
and R2 positions. (Exact KD values are given in the ESI, Tables S1–S5.†)
Fig. 4 Number of hits obtained in the H14 and H12 LSM pull-down
experiments and their affinity distributions.
This journal is © The Royal Society of Chemistry 2020
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View Article Onlinecould only be observed for protein S100B, while H14 displayed
more uniform affinity distribution.
Overall, these ndings indicated that H14 helical probes had
an overall ability to adapt to surface features of the protein set
studied. The stable, short, and bulky structure of H14 with its
closely packed side chains is free to reorient to attain the
optimum affinity as a local probe. Our conclusion was that the
H14 library exhibits superior properties for probing protein
surfaces. To validate protein binding of this library, selected
H14 LSM probes were synthesized separately and tested for
binding in the solution phase (see ESI for details, Fig. S2–6†).Foldameric LSMs detect orthosteric and non-orthosteric spots
Interactions between the H14 helical LSMs and the targets were
abundant, but safe recognition of the native PPI interfaces on
the targets is a criterion of druggability. To gain insight into the
ability of the LSMs to detect orthosteric spots, we carried out
pull-down assays in the presence of the native ligands (Table 2)
of the targets (Fig. 5). For highlighting the effect of the
competitor on the binding ngerprints, KD ratios and the LSM
replacement percentages were calculated and are represented
as heat maps (see ESI, Fig. S7†). We found that native ligands
radically changed the LSM affinity patterns for targets exhibit-
ing many direct protein–protein contacts (CaM, S100A4, S100B,
and RecQ-WH), and many of the LSM probes were displaced.
Since these proteins exhibit geometrically a single surface
region to form PPI interfaces, residual binders obviously inter-
acted with the non-orthosteric spots. In contrast, only a few LSM
probes displayed replacement for Gal-1. This could be explained
by the glycan selective native recognition domain of the protein.
We note that the replacement pattern for a single probe can, in
theory, be complex. While orthosteric weak-binder probes could
be completely replaced from interaction sites, high-affinity fol-
damer hits might bind to targets even in the presence of
competitors, although signicantly increased apparent KD
values clearly indicated orthosteric foldamer probes. Moreover,
a single probe can bind to both orthosteric and non-orthostericChem. Sci., 2020, 11, 10390–10398 | 10393
Table 2 Sequences and dissociation constants of the native ligands
applied as competitors
Protein Competitor KD
CaM TRPV1-Ct15 30.9  2.1 nM (ref. 32)
S100A4 NMIIA (1893–1923) 7  1 nM (ref. 83)
S100B RSK1 (689–735) 1.8 mM (ref. 83)
Gal-1 Lactose 409 mM (ref. 67)
RecQ-WH SSB-Ct8 16.6  0.8 mM (ref. 75)
Fig. 5 Competition pull-down experiments with the H14 LSM library.
KD heatmaps show side chain preferences using H14 helices alone and
in the presence of native ligands as competitors (left and right,
respectively). Foldamers with significant replacement percentages
(>80% for RecQ-WH, >90% for the other proteins) are marked with an
open circle, while foldamer hits with significant KD increase aremarked
with a filled circle. Exact KD values are given in Tables S1–S5.†
Chemical Science Edge Article
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View Article Onlinespots, which limits overall displacement levels. To avoid over-
looking interesting orthosteric weak binders, direct replace-
ment levels were assessed (see ESI, Fig. S7†).
Affinity patterns of foldameric LSMs are characteristic of the
target proteins
An important aspect of this study was to test if foldameric LSM
probes are able to distinguish proteins in terms of their PPI
forming behaviour. First, different levels of PPI promiscuities were
compared among test proteins using the overall ability to bind
LSM probes. PPI promiscuity was measured with the number of
known PPI partners in databases, BioGRID,61 Wiki-Pi,62 GPS-Prot,63
IntAct64 and APID65 (Fig. 2). False positive rates in proteomics range
from 20–34% (ref. 78 and 79) and databases may not provide exact
numbers of PPIs.80,81 Nevertheless, these data can be used to
indicate the magnitude of promiscuity and protein moon-
lighting.82 The binding promiscuity in foldameric LSM space was
estimated with the average bound fractions in the H14 library. A
connection was found between the number of database PPI part-
ners (NPPI) and the average bound fraction values obtained for the
H14 helical LSM probe library (Fig. 6, and ESI, Fig. S8†). Loga-
rithmic scaling is explained by exponential relationships between
the fragment space of LSM probes and the chemical space of full
proteins. This nding suggests that the overall affinity of the H14
LSM probes distinguishes among proteins with strongly different
levels of promiscuity. With this behaviour, foldameric LSM probes
displayed a biomimicking feature, an essential criterion for surface
mimetic drug design.
The ability to distinguish between proteins can also be
measured by similarity between the affinity patterns. Such
similarity was calculated using pairwise covariance of FB values
scaled to the theoretical maximum value for the 256-membered
library. Scaled covariance indicates maximum similarity with
a value of 100%, while zero covariance leads to 0%.
Results of the calculations are displayed for total (Fig. 7a)
and the orthosteric (Fig. 7b) binding fractions. Pairwise scaled
covariances were uniformly lower for the orthosteric binders,
showing that non-orthosteric binding obscured differences
between proteins as detected by the affinity pattern of the LSM
probes. This nding supports that the non-orthosteric binding
for these proteins can be considered non-specic in nature and
is a source of promiscuous behaviour for LSM probes. However,
non-orthosteric spots can contribute to allosteric sites, which
can be detected with the LSM probes. In this study, CaM,
S100A4, and S100B were selected as proteins with high levels of
structural and functional homology, albeit their specic roles10394 | Chem. Sci., 2020, 11, 10390–10398 This journal is © The Royal Society of Chemistry 2020
Fig. 6 Average bound fractions for the H14 helical LSM library
compared with the mean number of PPIs found in databases BioGRID,
Wiki-Pi, GPS-Prot, IntAct, and APID. For the lectin, Gal-1, NPPI is based
on ref. 66.
Fig. 7 Pairwise scaled covariances (%, maximum similarity: 100%, zero
covariance: 0%) of H14 LSM FB patterns calculated for total (a) and the
orthosteric (b) FB values. %. The sequence homologies of proteins are
given in panel (c).
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View Article Onlineand pathways in signal transduction are different and require
different PPI interfaces. Scaled covariances for the orthosteric
binders in the range of 13–20% were found among these
proteins. This low level of interface similarity detected by LSM
affinity patterns supports the conclusion that LSM probes are
able to distinguish the proteins with different functions even
with high levels of structural similarity (Fig. 7c).Fig. 8 Normalized frequencies obtained from literature data and
calculated for the H14 LSM library. Values fromWatkins et al.37 and Yan
et al.84 are based on computational Ala scanning and on PPI interface
analysis, respectively. LSM data were calculated from experimentally
determined FB data using eqn (2). The enrichment and depletion of
residues marked with asterisks (*) were found to be statistically
significant (Z-score, p < 0.05).Side chain binding propensities are biomimetic
Features at the level of the side chains that are responsible for
binding of LSM probes were also investigated. The analysis of
the affinity patterns revealed that binding affinity did not
depend on the dominant presence of highly hydrophobic cyclic
b-amino acid residues (ACHC and ACPC). If the sheer hydro-
phobic surface of these residues drove interaction with the test
proteins, higher uniform baseline binding would have been
observed. Many sequences displayed no signicant binding.
Interestingly, certain levels of diagonal symmetry could be
observed in the affinity maps (Fig. 3), suggesting that the
direction of the order of the R1 and R2 proteinogenic side chains
exhibits a limited effect on binding. These ndings indicate
that protein–LSM interactions are driven by proteinogenic side
chains present on the compact scaffold.
Focusing on the native-like anchor points, normalized
frequencies (wj) of the residues at protein-LSM contacts were
analysed. The literature denition of wj37 is given in eqn (1):This journal is © The Royal Society of Chemistry 2020wj ¼ fjP
m fm  vj
(1)
where fj is the number of interface residues of type j, and
normalization factor vj is the overall prevalence of the amino
acid of type j. Index m denotes the residue type. To approximate
residue frequencies based on bound fractions for the H14 LSM
library, the following formula was applied:
wj ¼
P
iF
i;j
B
2PiF iB  vj
¼
P
iF
i;j
B
2PiF iB  0:0625
(2)
Index i denotes the LSM sequence, and index j is the residue
type. FB
i,j is the bound fraction of the LSM probe i, if it contains
residue type j. FB
i,j is zero, if sequence i does not contain residue
type j. This formula assumes that a binder LSM probe has both
proteinogenic side chains in contact with the protein interface.
The LSM library was uniform with respect to the 16 side chains,
and therefore vj ¼ 1/16 ¼ 0.0625 was applied as a uniform
normalization factor. Normalized frequencies were compared
with literature data dissecting large datasets from the Protein
Data Bank: (i) computational Ala scanning categorized by
secondary structure types37 and (ii) protein–protein interface
analysis, dening interface residues with a maximum distance
of 6 Å for the contacting residues84 (Fig. 8, calculation details in
the ESI†).
The LSM library displayed enrichment for residues W, F, Y,
I, L, M, V, and R and overall depletion for residues A, D, E, N, Q,
S, and T was observed. Statistically signicant (Z-score, p < 0.05)
changes were observed forW, F, I, L, D, E, N, S and T (Table S6†).
These results are qualitatively consistent with analyses of the
PPI interface databases that demonstrate enrichment of
aromatic37,84 and aliphatic side chains at PPI interfaces,85 along
with the importance of ion pair interactions.84,86 Interestingly,
engineered proteins exhibit a more dominant enrichment inChem. Sci., 2020, 11, 10390–10398 | 10395
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View Article Onlinearomatic and ionic residues.87 However, variations of the side
chain frequencies have been observed across different struc-
tural databases.37,84,85,88,89
For the test protein set, side chain frequency levels were
dependent on specic proteins (see ESI, Fig. S9†), and
enrichment/depletion values can be associated with the selec-
tivity of PPI interactions. Initially, foldameric LSM probes were
hypothesized to respond to key side chain requirements of
binding at orthosteric sites, especially sites involving electro-
static and H-bonding interactions.
For CaM, a high-affinity interaction is possible only if
cationic residues are present in specic patterns on the mostly
hydrophobic helical interface.90 Inspection of binding data
(Fig. 3) clearly revealed that residues Lys and Arg were enriched
in the binder LSM probes. S100A4 interacts with sequences
containing Ser, Thr, and Met as key residues.91 The selection
toward these side chains is evident in binding ngerprints of
S100A4. Protein S100B displays different binding preferences
compared with S100A4.92 In protein complexes of S100B,
besides Leu and Ile, cationic side chains are also prevalent as
anchoring points of interacting partners.83,93–95 NMR experi-
ments reported that the binding surface of the S100B-p53
peptide complex is dened by Arg, Lys, Leu, and Ile residues
of p53, forming salt bridges with Glu side chains and partici-
pating in hydrophobic contacts with a hydrophobic patch on
S100B.83,93–95 As opposed to S100A4, the specic Arg–Lys block
was observed in LSM probe binding ngerprints of S100B.
Gal-1 and the RecQ-WH domain were models for proteins
with a low tendency to form direct protein–protein complexes.
Gal-1 does not exhibit preference for specic hydrophilic side
chains, and accordingly, its LSM affinity pattern did not show
a tendency to bind other than hydrophobic side chains. The
binding cle of RecQ-WH includes a hydrophobic gra anked
by polar and positively charged residues96 that recognizes the
intrinsically disordered and highly anionic C-terminal of SSB97
(DFDDDIPF). This segment ts into a narrow and slightly bent
site on RecQ-WH. As expected, surface mapping of RecQ-WH
with bulky LSM probes led to a low number of hits. Even the
propensity of the protein to bind anionic sequences did not
drive anionic LSM probes to the binding site, possibly because
of steric incompatibility.
These ndings suggest that the protein interfaces studied
select preferred side chain chemistries from the LSM probe
library in a manner similar to selection of natural partners. On
this ground, we concluded that LSM probes exhibit biomimetic
features in presenting proteinogenic side chains for their
protein partners.
Conclusions
Foldameric LSM probe libraries were constructed with H14 and
H12 scaffolds and were tested with ve proteins. Affinity patterns
of 512 LSM probes were recorded, and the resulting 2560 protein–
foldamer interactions were analysed using a fragment-centric
approach. LSM affinities were secondary structure dependent,
and a sufficient number of hits in the affinity range of 1–150 mM
was obtained for the hexameric H14 library. Binding was driven10396 | Chem. Sci., 2020, 11, 10390–10398by two proteinogenic side chains displayed. The hydrophobic
foldamer scaffold served as a template and solvent shield. The
better performance of H14 LSM probes may be explained by their
ability to geometrically adapt their stable and bulky skeleton to
the local environment at protein hot spots. Foldameric LSMs
sensitively probed protein surfaces, and thus, detected both
orthosteric and non-orthosteric hot spots, based on competition
experiments. Orthosteric hits identied in this way along with
their geometrically conned binding to the PPI interface offer the
possibility of linking them to a high-affinity ligand. This concept
was demonstrated earlier in a dynamic covalent system with
CaM.32 Despite the limited structural complexity of LSM probes,
affinity ngerprints were characteristic of target proteins. The
overall tendency to bind LSM probes correlates with the number
of PPI partners identied for the protein. Pairwise correlations
between orthosteric binding patterns remained low even for
proteins with high structural homology. LSM probes are thus
sensitive to the function encoded by PPI interfaces. LSM probes
achieve such biomimetic behaviour by presenting proteinogenic
side chains in a manner similar to natural PPIs. This behaviour is
reected in protein-like enrichment and depletion values ob-
tained for the side chain chemistries.Moreover, test proteins were
able to select key residue types needed for specic PPI recognition
patterns from the libraries.
In the early days of chemical biology, Linus Pauling
proposed target-induced self-organization of biopolymers as
a possible mechanism to generate high-affinity ligands against
proteins.98 His chemistry-inspired concept did not explain the
operation of the adaptive immune system, but Pauling's inge-
nious idea is still there mostly untapped to offer a route to
synthetic biopolymers that mimic molecular recognition prop-
erties of natural antibodies. This work takes a step toward
Pauling's concept, using self-organizing protein mimetic LSM
probes as promising candidates for recognition segments. An
additional understanding of dynamic covalent chemistry may
eventually solve the problem of in situ coupling.
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